We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Test Kit Identifies Genetic Risk of Thrombosis
Product News

Test Kit Identifies Genetic Risk of Thrombosis

Test Kit Identifies Genetic Risk of Thrombosis
Product News

Test Kit Identifies Genetic Risk of Thrombosis


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Test Kit Identifies Genetic Risk of Thrombosis"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Astra Biotech GmbH has announced a new genetic test kit which identifies hereditary thrombophilia - a significant risk factor in the development of potentially life-threatening deep vein thrombosis and pulmonary embolism.

In line with the company’s aim of facilitating disease prevention and improving quality of life, the Astra Thrombosis kit detects three common mutations which disrupt the blood coagulation mechanism.

The consequences of thrombosis can be severe - pulmonary embolism (PE), myocardial infarction, stroke and infertility - and thrombosis is one of the most widespread causes of morbidity and mortality in developed countries.

Hereditary thrombophilia, the propensity to develop thrombosis, is an important factor influencing development of deep vein thrombosis (DVT) and PE.

Additional risk factors include pregnancy, prolonged immobilization, surgical intervention, injury and smoking.

The Astra Thrombosis kit enables identification of hereditary thrombophilia and estimation of a patient’s risk of developing DVT and PE.

Following extraction of the patient’s total DNA sample from blood tissue or epithelium, three single nucleotide polymorphisms in the F5, F2 and MTHFR genes can be simultaneously detected using the kit.

The method is multiplex PCR with subsequent restriction and polyacrylamide or agarose gel electrophoresis. The diagnostic kit includes two PCR mixes, positive controls, DNA-polymerase, restriction enzyme and buffer.

Testing for hereditary thrombophilia is recommended in various circumstances, such as venous embolism occurring before the age of 50, repeatedly, or during pregnancy or the postnatal period, and for members of families with expressed hereditary thrombophilia.

Advertisement